Search

everythinglearnresearchcommunity

for

Search:↓

Phenobarbital-loaded chitosan nanoparticles are promising for preventing hair loss from chemotherapy.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

Anthracycline and taxane chemotherapy cause significant side effects like fatigue, vomiting, nausea, nerve damage, joint pain, and hair loss in breast cancer patients.

Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.

Eclipta alba extract may work as an anticancer agent and help reverse drug resistance.

Rubbing vitamin D3 on skin can help prevent hair loss from chemotherapy and slow breast tumor growth in mice.

A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.

Gefitinib can cause hair loss without scarring.

Activated ras can protect kidney cells from a certain substance that causes cell death.

Albendazole and praziquantel can cause severe side effects, especially with prolonged use or liver issues.

A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.

Suppressing eIF4E can prevent hair loss from chemotherapy.

A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.

Reducing gefitinib dosage improved hair loss, but scarring remained.

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

The formula YH0618 can reduce the harmful side effects of the chemotherapy drug Doxorubicin and protect healthy cells.

EGFR inhibitors in breast cancer treatment can cause serious skin issues affecting patient quality of life.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

CXXC5 can both suppress and promote cancer, making it a complex target for treatment.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Photodynamic therapy successfully treated skin cancer in a 53-year-old woman.

Baricitinib was effective in treating both early and late onset alopecia areata.